Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...
Two clinical trials presented last week at the Conference on Retroviruses and Opportunistic Infections ... Islatravir is a new type of antiretroviral drug, a nucleoside reverse transcriptase ...
MedPage Today on MSN1d
Daily Oral Islatravir and Doravirine Just as Effective as Other ART Regimens for HIVSwitching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...
These results were presented today at the Conference on Retroviruses and Opportunistic Infections ... with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...
New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...
These results were presented today at the Conference on Retroviruses and Opportunistic ... a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland Unlimited ...
the previous treatment (if including TDF [tenofovir disoproxil fumarate] or NNRTIs [non-nucleoside reverse transcriptase inhibitors]) may play a significant role." The researchers concluded that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback